The Clinical Diagnostic Value of Serum Cystatin C in Patients with Prostate Cancer

Jiayu Mo; Huawu Huang; Baode Lu; Yuchun Xu; Lishuang Huang

doi:10.54097/z43zp030

Authors

Jiayu Mo
Huawu Huang
Baode Lu
Yuchun Xu
Lishuang Huang

DOI:

https://doi.org/10.54097/z43zp030

Keywords:

Prostate Cancer, Cystatin-C, Tumor Suppressor

Abstract

Objective To investigate the value of serum cystatin C (Cys-C) in the clinical diagnosis of prostate cancer patients (PCa). Methods We utilized data from the 2001-2002 National Health and Nutrition Examination Survey (NHANES) cycle. Variables were downscaled by LASSO regression to screen for influencing factors, and parallel multifactorial cox regression analyses were performed to assess the association between Cys-C and prostate cancer, as well as restricted cubic spline (RCS) analyses. Subgroup analyses by age, education, race, body mass index, and smoking history were also performed. The correlation between age and Cys-C was analyzed using Spearman's correlation analysis. Results Mean ± standard deviation (SD) Cystatin C levels were higher than normal in prostate patients. The ratios (95% confidence intervals) of the univariate and multivariate models I, II and III were 1.6117 (0.0412,0.9144), 1.5841 (-0.0192,0.8819), and 1.3357 (-0.3876,0.8454), respectively. Restricted cubic spline regression analysis did not show a nonlinear correlation between cystatin C and PCa (nonlinear p=0.007). Spearman's correlation analysis showed that serum cystatin C levels were statistically significantly correlated with age (r=0.476,P<0.01). Kaplan⁃Meier survival curves showed that patients with high levels of Cystatin C had a faster downward trend in the survival curves. Elevated Cys-C was significantly associated with an increased risk of PCa, and prostate cancer patients with elevated Cys-C had a shorter time to survival and a lower survival rate. Conclusion Cys-C is positively correlated with the presence of PCa, serum Cys-C level has significant correlation with age, and Cys-C should be given clinically can be used as an auxiliary diagnostic index for regular monitoring of prostate cancer patients of different ages and normal people.

Downloads

Download data is not yet available.

References

[1] Felgueiras J, Silva J V, Fardilha M. Prostate cancer: the need for biomarkers and new therapeutic targets[J]. J Zhejiang Univ Sci B, 2014,15(1):16-42.

[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.

[3] Rawla P. Cardiac and vascular complications in rheumatoid arthritis[J]. Reumatologia, 2019,57(1):27-36.

[4] Cuzick J, Thorat M A, Andriole G, et al. Prevention and early detection of prostate cancer[J]. Lancet Oncol, 2014,15(11): e484-e492.

[5] Fenton J J, Weyrich M S, Durbin S, et al. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force[J]. JAMA, 2018,319(18):1914-1931.

[6] Monsouvanh A, Proungvitaya T, Limpaiboon T, et al. Serum cathepsin B to cystatin C ratio as a potential marker for the diagnosis of cholangiocarcinoma[J]. Asian Pac J Cancer Prev, 2014, 15(21):9511-9515.

[7] Chew-Harris J S, Florkowski C M, George P M, et al. Comparative performances of the new chronic kidney disease epidemiology equations incorporating cystatin C for use in cancer patients[J]. Asia Pac J Clin Oncol, 2015,11(2):142-151.

[8] Kulcsar-Jakab E, Petho Z, Pap Z, et al. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study[J]. BMC Musculoskelet Disord, 2015,16:227.

[9] WANG Jing, WANG Huanhuan, ZHANG Shaocheng. Laboratory evaluation of serum cystatin C levels in prostate cancer patients[J]. International Journal of Laboratory Medicine, 2016,37(12):1697-1698.

[10] SUN Jianguo, CHEN Zhengtang. Relationship between cysteine protease inhibitor C and malignant tumors[J]. Chinese Journal of Tumor Control, 2010,17(15):1235-1237.

[11] Wegiel B, Jiborn T, Abrahamson M, et al. Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways[J]. PLoS One, 2009,4(11): e7953.

[12] LI Xuan-Yu, HAO Lin, HAN Cong-Hui. Diagnostic value of FIB, D-dimer and serum CysC in prostate cancer bone metastasis[J]. China Medical Journal, 2022,19(14):97-100.

[13] Jiborn T, Abrahamson M, Wallin H, et al. Cystatin C is highly expressed in the human male reproductive system[J]. J Androl, 2004,25(4):564-572.

[14] WANG Xue'an, NIU Qian, HUANG Min, et al. Correlation between serum cystatin C levels and clinical scores in prostate cancer patients[J]. Journal of Clinical Urology, 2021,36 (03): 182-185.

[15] Jamshidi A, Liu M C, Klein E A, et al. Evaluation of cell-free DNA approaches for multi-cancer early detection[J]. Cancer Cell, 2022,40(12):1537-1549.

[16] Liao X, Zhu Y, Xue C. Diagnostic value of serum cystatin C for diabetic nephropathy: a meta-analysis[J]. BMC Endocr Disord, 2022,22(1):149.

[17] Ding L, Liu Z, Wang J. Role of cystatin C in urogenital malignancy[J]. Front Endocrinol (Lausanne), 2022,13: 1082871.

[18] Guo K, Chen Q, He X, et al. Expression and significance of Cystatin-C in clear cell renal cell carcinoma[J]. Biomed Pharmacother, 2018,107:1237-1245.

[19] Guo S, Xue Y, He Q, et al. Preoperative serum cystatin-C as a potential biomarker for prognosis of renal cell carcinoma[J]. PLoS One, 2017,12(6): e178823.

[20] Zhang Z, Zhan F. Type 2 Cystatins and Their Roles in the Regulation of Human Immune Response and Cancer Progression[J]. Cancers (Basel), 2023,15(22).